BRIEF COMMUNICATION

Special Issue: Current evidence and perspectives for hypertension management in Asia

Long-term outcome of renal nerve denervation (RDN) for resistant hypertension

Pariya Panchavinnin1 · Sirisawat Wanthong2 · Weranuj Roubsanthisuk2 · Damras Tresukosol1 · Peera Buranakitjaroen3 · Chavalit Chotruangnapa2 · Wattana Watana3 · Rungtiwa Pongakasira4 · Nattawut Wongpraparut

Received: 25 October 2021 / Revised: 11 March 2022 / Accepted: 16 March 2022 / Published online: 7 April 2022
© The Author(s) 2022. This article is published with open access

Abstract
We aimed to determine the long-term outcome of renal denervation (RDN). All patients with resistant hypertension who underwent RDN between 2012 and 2018 at Siriraj Hospital were included in the study. Patients were followed up at 3, 6, and 12 months and then annually up to 9 years. Effectiveness of the RDN outcome was defined by either (1) a reduction in office systolic BP ≥ 10 mmHg, (2) a reduction in the number of antihypertensive drugs taken, or (3) both outcomes being achieved. In total, 18 RDN procedures were performed during the study period. The mean and longest follow-up periods were 52 months and 104 months, respectively. Heterogeneous BP responses after RDN for resistant hypertension were observed. Effectiveness of the RDN outcome was achieved in 88% of the patients at 1 year and in >80% of the patients during the entire follow-up at each time point up to 9 years.

Keywords Resistant hypertension · Renal nerve denervation · Long-term outcome

Introduction
Resistant hypertension is defined as seated office blood pressure (BP) > 140/90 mmHg in a patient treated with three or more antihypertensive medications at optimal (or maximal tolerated) doses, including a diuretic, and after excluding pseudoresistance as well as drug-induced hypertension and secondary hypertension [1]. Initially, our case series of resistant hypertension patients who underwent renal denervation (RDN) showed sustained BP reduction at 6 months [2]. Asian patients with resistant hypertension are a target population of RDN treatment [3, 4]. Doubts were cast on its efficacy when the SYMPLICITY HTN-3 study did not show a statistically significant BP reduction in RDN compared to sham treatment [5]. SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED reported significant systolic BP reductions of more than 5 mmHg in the RDN groups regardless of whether hypertensive drug naïve or persistent patients were involved [6, 7]. However, the patients in those trials were patients with mild to moderate hypertension. Data on the long-term efficacy of RDN in resistant hypertension remain lacking. Consequently, we aimed to assess the long-term efficacy of RDN in resistant hypertension.

Methods
The Siriraj Institutional Review Board (SIRB) of the Faculty of Medicine Siriraj Hospital, Mahidol University approved this study (COA no. Si 252/2013), and the study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki. All of the resistant hypertension patients who underwent percutaneous renal nerve denervation at our institution between 2012 and 2018 were included in the study. The patients’ baseline demographics were recorded. The number and dose of antihypertensive medications before and after RDN were recorded. Office BP
measurement was performed while patients sat with their arms resting on the table with the mid-arm at heart level and the back supported on the chair in a quiet room and relaxed for 5 min. Smoking and caffeine were avoided. The BP cuff was sized according to the individual arm cuff. Three BP measurements were performed and calculated based on the average of the last 2 measurements. Procedural data, including the procedure time, premedication, renal angiography data, and area and number of radiofrequency ablations, were recorded. RDN was performed according to a standard protocol. Patients were followed up at 3 months and 6 months after the procedure and then annually up to 9 years.

Results

Between 2012 and 2018, 17 patients who underwent 18 RDN procedures were included in the study, and their records were reviewed. The patients had a mean systolic BP of 168.6 ± 22.7 mmHg despite taking 5.2 ± 1.2 antihypertensive drugs. The baseline clinical characteristics are shown in Table 1. The prevalence of accessory renal arteries in this study was 11.8% (2 patients). The first 7 patients (38.9%) underwent RDN using a Symplicity catheter®, while the latter 11 patients (61.1%) used a Symplicity Spyral catheter®. The median RDN time was 39 min (IQR 25–62 min), with a median total catheter lab time of 64 min (46–85 min). There was a median of 20 (IQR 16–24) total successful ablations performed. RF ablation was performed at the distal branch in 11 patients (61.1%). One patient developed renal artery vasospasm, which was successfully treated with IA nitroglycerin. There were no long-term complications related to the procedures.

Of all the cases, the longest follow-up was 104 months, with a mean follow-up period of 52.39 ± 30.96 months. The reduction in systolic BP was greater immediately after the procedure, with a mean change in systolic BP of −31.9 ± 17.3 mmHg at the date of discharge, −24.3 ± 32.0 mmHg at 6 months, −16.8 ± 32.3 mmHg at 1 year, −15.3 ± 29.4 mmHg at 3 years, −15.3 ± 35.2 at 5 years, −14.8 ± 27.9 at 7 years, and −30.0 ± 12.7 at 9 years. The average antihypertensive drugs received by the patients decreased from 5.2 ± 1.2 at baseline to 4.7 ± 1.3, 3.6 ± 1.6, 3.7 ± 1.7, and 4.1 ± 1.6 at the date of discharge, 6-month, 1-year, and 2-year follow-ups, respectively, and were sustained at 4 drugs after the 2-year follow-up. Three patients had non-cardiac death during the follow-up period.

There is a heterogeneity in the magnitude of BP responses after RDN in resistant hypertension. The mean systolic BP reduction was −24.3 ± 32.0 mmHg at 6 months, but the range of the systolic BP difference between baseline and 6 months was −72 mmHg to +40 mmHg. The heterogeneous BP responses after RDN in resistant hypertension are demonstrated in Graphical Abstract Fig. 1A. This outcome could be partly affected by the adjustment of antihypertensive medication. We assessed the effectiveness of the renal denervation procedure in achieving a reduction in systolic BP of ≥10 mmHg, a reduction in the number of antihypertensive drugs, or both outcomes being achieved.

Graphical Abstract
Heterogenous BP responses after RDN for resistant hypertension. The bar graph represents the difference in SBP at 6 months after RDN compared with the baseline SBP, for each patient (1A). Efficacy of the renal denervation procedure. Percentage of patients whose SBP decreased ≥10 mmHg from baseline or whose medication decreased from baseline (1B).

Point of view

Clinical relevance
Effectiveness of the RDN outcome was achieved in >80% of the patients with resistant hypertension and was maintained over a long-term follow-up without any intervention-related adverse events.
Future direction
A long-term study to assess the effect of RDN on cardiovascular outcomes is warranted.

Consideration for the Asian population.
RDN should be considered as an adjunct treatment in addition to antihypertensive therapy in Asian patients with resistant hypertension.
antihypertensive drugs or both, as shown in Graphical Abstract Fig. 1B. Effectiveness of the RDN outcome was achieved in >80% of the patients during the entire follow-up at each time point.

Repeated renal denervation

One patient in our study underwent a second RDN due to a resurgence of BP after her first RDN. Her office blood pressure was raised to 184/110 mmHg and 196/113 mmHg at the fourth and fifth years of follow-up, respectively. After her second RDN, her BP dramatically decreased to 102/68 mmHg. Furthermore, she was also able to decrease her antihypertensive drugs taken from 5 drugs to 2 drugs.

Discussion

The present study investigated the long-term effectiveness of RDN outcomes in patients with resistant hypertension. The main findings of the study were as follows: (1) there was heterogeneity in the magnitude of BP reduction from baseline at the 6-month follow-up after RDN; (2) effectiveness of the RDN outcome was achieved in >80% of the patients during the entire follow-up at each time point up to 9 years; and (3) rebound hypertension occurred in 1 patient but was then successfully treated with re-do RDN.

This study provided long-term data on the effective outcome of RDN for resistant hypertension, and this effectiveness was sustained for up to 9 years without any intervention-related adverse events. The GSR reported the 3-year outcome after RDN. Systolic BP reduction after RDN was sustained over 3 years, with a mean systolic BP (−16.5 ± 28.6 mmHg) [8] and (−32 ± 18.8 mmHg) in GSR Korea [9]. The findings of a greater effect of RDN on long-term BP reduction in Asia were consistent with a prior report by Kario et al. [10].

Effectiveness of the RDN outcome was achieved in >80% of the patients during the entire follow-up at each time point. The heterogeneous BP responses after RDN were mainly from appropriate patient selection. Patient preference should also be part of the decision-making in patient selection [11]. The ideal candidates for RDN are patients with autonomic hypersensitivity. Several studies have shown the benefit of autonomic function in guided selection of patients who are good responders to RDN. The use of cardiac baroreflex sensitivity (BRS), heart rate variability (HRV) and baseline 24-hour HR > 73.5 beats per minute (BPM) in predicting good responders to RDN was proposed [12–14]. From our ambulatory BP monitoring (ABPM) data, all of the patients with baseline pre-RDN 24-hour HR > 73.5 BPM exhibited effectiveness of the RDN outcome at 6 months. Esler et al. suggested the clinical characteristics of patients with neurogenic hypertension, such as hypertensive patients with obesity, obstructive sleep apnea (OSA), isolated systolic hypertension in the young, or a high ambulatory HR [13]. Other clinical clues of sympathetic hypersensitivity, such as OSA and atrial fibrillation, could also help identify patients. All three patients with OSA in our study were good responders after RDN.

Rebound hypertension occurred in 1 patient. This patient had undergone a second RDN because of a resurgence of

| Variables | N=18 |
|-----------|------|
| Age (years) | 61.1 ± 17.7 |
| Female | 12 (66.7) |
| BMI (kg/m²) | 29.3 ± 5.3 |
| eGFR (ml/minute/1.73 m²) | 59.4 (35.8,80.4) |
| eGFR ≤ 60 ml/min/1.73 m² | 9 (50.0) |
| OSA | 3 (16.7) |
| Stroke and TIA a | 4 (22.2) |
| DM | 10 (55.6) |
| CAD a | 9 (50.0) |
| SBP (mmHg) | 168.6 ± 22.7 |
| DBP (mmHg) | 81.1 ± 21.4 |
| HR (bpm) | 87.3 ± 19.9 |

Pre-RDN ABPM (n = 9)

24 h SBP (mmHg) 170.50 ± 38.58
24 h DBP (mmHg) 89.25 ± 41.12
24 h HR (bpm) 90.25 ± 28.06
Daytime SBP (mmHg) 169.25 ± 43.95
Daytime DBP (mmHg) 90.50 ± 44.38
Daytime HR (bpm) 90.25 ± 27.44
Nighttime SBP (mmHg) 176.25 ± 23.34
Nighttime DBP (mmHg) 89.25 ± 37.92
Nighttime HR (bpm) 81.00 ± 18.71

Number of antihypertensive drugs 5.2 ± 1.2
ACEI/ARB 16 (88.9)
Beta-blocker 15 (83.3)
CCB 16 (88.9)
Diuretic group 14 (77.8)
Aldosterone antagonist 4 (22.2)
Alpha-blockers 12 (66.7)

Data presented as number and percentage, mean ± standard deviation, or median (IQR)

BMI body mass index, eGFR estimated glomerular filtration rate, OSA obstructive sleep apnea, TIA transient ischemic attack, DM diabetes mellitus, CAD coronary artery disease, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, ABPM ambulatory blood pressure monitoring, CCB calcium-channel blockers, ACEI angiotensin converting enzyme inhibitors, ARB angiotensin II receptor blockers

aThese events occurred >12 months before the procedure
BP after the fourth year. Booth et al. found reinnervation 11 months after denervation in an animal study [15]. The successful reduction of BP in the repeated RDN of our case was similar to the results from recent reports/case series.

In terms of limitations, this study was a registry. Blood pressure assessment was office blood pressure, not 24-hour ABPM.

Asian perspectives

Ethnic differences in hypertension characteristics, hypertension-related cardiovascular disease (CVD) and BP reduction after RDN were reported between Asian and other ethnicities. Stroke occurs more frequently than myocardial infarction in Asian countries compared to Western countries [16]. Asians have more prevalent masked hypertension, which is associated with increased CVD risks [17]. Moreover, greater BP reduction after RDN in Asian versus non-Asian patients was observed [10]. This study provides long-term data on RDN effectiveness. Further research should be conducted to assess mortality and CVD outcomes after RDN in Asians versus other ethnicities.

Conclusion

There is heterogeneity in the magnitude of BP responses after RDN in resistant hypertension. Effectiveness of the RDN outcome was achieved in >80% of the Thai patients with resistant hypertension and was maintained over a long-term follow-up without any intervention-related adverse events.

Funding This study was supported by a grant from the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Compliance with ethical standards

Conflict of interest All authors declare that they have no known competing financial interests or personal relationships that have or could be perceived to have influenced the work reported in this article.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Unger T, Borghi C, Charchar F, Khan NA, Poulier NR, Prabhakaran D, et al. 2020 International Society of hypertension global hypertension practice guidelines. Hypertension 2020;75:1334–57.
2. Wongparparut N, Tresukosol D, Roubiansuk W, Buranakitjaroen P, Chotivoraniyakul C, Pongkasira E. Effect of renal nerve denervation for resistant hypertension in Thai patients: a report of the first cases series in Thailand. J Med Assoc Thai. 2014;97: S155–61.
3. Wang TD, Lee YH, Chang SS, Tung YC, Yeh CF, Lin YH, et al. 2019 consensus statement of the Taiwan Hypertension Society and the Taiwan Society of Cardiology on renal denervation for the Management of Arterial Hypertension. Acta Cardiol Sin. 2019; 35:199–230.
4. Kario K, Kim BK, Aoki J, Wong AY, Lee YH, Wongparparut N, et al. Renal Denervation in Asia: Asia Renal Denervation Consortium. Hypertension 2020;75:590–602.
5. Bhatt DL, Kandzari DE, O’Neill WW, D’Agostino R, Flack JM, Katzen BT, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370:1393–401.
6. Kandzari DE, Böhm M, Mahfoud F, Townesend RR, Weber MA, Pocock S, et al. Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-OFF MED proof-of-concept randomised trial. Lancet.2018;391:2346–55.
7. Böhm M, Kario K, Kandzari DE, Mahfoud F, Weber MA, Schmidt RE, et al. Efficacy of catheter-based renal denervation in the absence of antihypertensive medications (SPYRAL HTN-OFF MED Pivotal): a multicentre, randomised, sham-controlled trial. Lancet.2020;395:1444–51.
8. Mahfoud F, Böhm M, Schmieder R, Narkiewicz K, Ewen S, Ruijlope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J. 2019;40:3474–82.
9. Kim BK, Kim HS, Park SJ, Park CG, Seung KB, Gwon HC, et al. Long-term outcomes after renal denervation in an Asian population: results from the Global SYMPLICITY Registry in South Korea (GSR Korea). Hypertens Res. 2021;44:1099–104.
10. Kario K, Wang TD. Perspectives of renal denervation from hypertension to heart failure in Asia. Hypertens Res. 2022;45: 193–7.
11. Kario K, Kagitani H, Hayashi S, Hanamura S, Ozawa K, Kanegae H. A Japan nationwide web-based survey of patient preference for renal denervation for hypertension treatment. Hypertens Res. 2022;45:232–40.
12. Zuern CS, Eick C, Rizas KD, Bauer S, Langer H, Gawaz M, et al. Impaired cardiac baroreflex sensitivity predicts response to renal sympathetic denervation in patients with resistant hypertension. J Am Coll Cardiol. 2013;62:2124–30.
13. Esler M. Does increased 24-h ambulatory heart rate identify de facto neurogenic hypertension, and facilitate selection of hypertensive patients for renal denervation? Eur Heart J. 2019;40: 752–4.
14. Hoogerwaard AF, de Jong MR, Adiyaman A, Smit JJJ, Delnoy P, Heeg JE, et al. Renal sympathetic denervation induces changes in heart rate variability and is associated with a lower sympathetic tone. Clin Res Cardiol. 2019;108:22–30.
15. Booth LC, Nishi EE, Yao ST, Ramchandra R, Lambert GW, Schlaich MP, et al. Reinnervation of renal afferent and efferent
nerves at 5.5 and 11 months after catheter-based radiofrequency renal denervation in sheep. Hypertension. 2015;65:393–400.
16. Ueshima H, Sekikawa A, Miura K, Turin TC, Takashima N, Kita Y, et al. Cardiovascular disease and risk factors in Asia: a selected review. Circulation. 2008;118:2702–9.

17. Fujiwara T, Yano Y, Hoshide S, Kanegae H, Kario K. Association of cardiovascular outcomes with masked hypertension defined by home blood pressure monitoring in a Japanese General Practice Population. JAMA Cardiol. 2018;3:583–90.